ЖурналыПодпискаАрхивКнигиПроектыО насРекламаДоставка/ОплатаКонтакты
+7 (495) 482-43-29
  • Главная
  • / Журналы
  • / Вернуться в журнал
  • / Содержание номера
  • / Статья
Evaluation of the neuroprotective activity of Mexidol in a model of hemorrhagic stroke

Evaluation of the neuroprotective activity of Mexidol in a model of hemorrhagic stroke

Authors:
Алексей Владимирович Щулькин,
Иван Владимирович Черных,
Сергей Константинович Правкин,
Юлия Владимировна Абаленихина

Журнал: Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2026;126(3-2):40-45.

DOI: 10.17116/jnevro202612603240

Read: 1086 раз

Download PDF (RU)Download PDF (EN)

Abstract

OBJECTIVE

To comprehensively evaluate the neuroprotective potential of Mexidol following systemic administration in various dosage forms in a model of hemorrhagic stroke.

MATERIAL AND METHODS

The study was performed on 130 outbred male rats, weighing 180—200 g and aged 7—8 weeks. All animals were divided into 3 series: Series 1 — intravenous administration of Mexidol at doses of 50 and 100 mg/kg; Series 2 — intramuscular administration at doses of 50 and 100 mg/kg; Series 3 — intragastric administration at doses of 50, 100, and 200 mg/kg. Acute hemorrhagic stroke was modeled by administering autologous blood at a volume of 0.05 ml/kg body weight into the region of the internal capsule of the right hemisphere. Mexidol administration was initiated 30 minutes after modeling acute focal stroke. Twenty-four hours after the surgery, the severity of neurological deficit was assessed using the McGraw Stroke-Index Scale modified by I.V. Gannushkina. Subsequently, the animals were euthanized, the brain was isolated, fixed in formalin, and tomography was performed.

RESULTS

Intravenous administration of Mexidol at a dose of 100 mg/kg led to a statistically significant reduction in the severity of clinical symptoms 24 hours after surgery compared to control animals. Intramuscular administration produced a similar effect at doses of 50 and 100 mg/kg, while intragastric administration did so at doses of 100 mg/kg and 200 mg/kg. Intravenous and intramuscular administration of Mexidol at doses of 50 and 100 mg/kg did not affect the size of the brain lesion in rats, whereas intragastric administration of Mexidol at a dose of 200 mg/kg led to its reduction.

CONCLUSION

The obtained results indicate that, in cases of small intracranial hematomas (e.g., those remaining after surgical removal of the initial hematoma), Mexidol exerts a pronounced neuroprotective effect.

Keywords

  • Mexidol
  • neuroprotection
  • hemorrhagic stroke

Дата поступления: 18.02.2026

Дата принятия в печать: 27.02.2026

Дата публикации: 06.04.2026

References
  1. Feigin VL, Stark BA, Johnson CO, et al. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):1-26. https://doi.org/10.1016/S1474-4422(21)00252-0
  2. Kurepina IS, Zorin RA, Zhadnov VA, et al. Nonuniform course of acute period of hemorrhagic stroke: analysis using methods of multivariate stat. Eruditio Juvenium. 2021;9(1):59-67. (In Russ.). https://doi.org/10.23888/HMJ20219159-67
  3. Maida CD, Norrito RL, Rizzica S, et al. Molecular pathogenesis of ischemic and hemorrhagic strokes: background and therapeutic approaches. Int J Mol Sci. 2024;25(12):6297. https://doi.org/10.3390/ijms25126297
  4. Kalinin RE, Suchkov IA, Pshennikov AS, et al. Evaluation of Cognitive and Biochemical Brain Status in Patients after Carotid Endarterectomy. I.P. Pavlov Russian Medical Biological Herald. 2023;31(4):601-612. (In Russ.). https://doi.org/10.17816/PAVLOVJ585436
  5. Campbell BCV, Khatri P. Stroke. Lancet. 2020;396(10244):129-142. https://doi.org/10.1016/S0140-6736(20)31179-X
  6. Magid-Bernstein J, Girard R, Polster S, et al. Cerebral hemorrhage: pathophysiology, treatment, and future directions. Circ Res. 2022;130(8):1204-1229. https://doi.org/10.1161/CIRCRESAHA.121.319949
  7. Voronina TA, Litvinova SA, Gladysheva NA, et al. The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(5):22-33. (In Russ.). https://doi.org/10.17116/jnevro202512505122
  8. Shchulkin AV. Effect of mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(2):35-39. (In Russ.).
  9. Shchulkin AV, Chernykh IV, Abalenikhina YuV, et al. The effect of Mexidol on the level of neurogenesis markers in acute cerebrovascular accident in the experiment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(2):107-112. (In Russ.). https://doi.org/10.17116/jnevro2025125021107
  10. Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(3-2):55-65. (In Russ.). https://doi.org/10.17116/jnevro20171173255-65
  11. Shamalov NA, Fedin AI, Rakhimbaeva GS, et al. Results of the international multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of the sequential therapy with ethylmethylhydroxypyridine succinate in patients in the acute and early recovery periods of ischemic stroke (MIR). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(8-2):40-53. (In Russ.). https://doi.org/10.17116/jnevro202512508240
  12. Kurdyumov IN, Gan’shina TS, Maslennikov DV, et al. Influence of mexidol and hemisuccinate 2-ethyl-6-methyl-3-hydroxypyridine on cerebral hemodynamics at hemorrhagic and ischemic damage of brain. Eksp Klin Farmakol. 2019;82(5):3-6. (In Russ.). https://doi.org/10.30906/0869-2092-2019-82-2-3-6
  13. Kraineva VA. The experimental study of peculiarities and mechanism of neuroprotective action of mexidol in hemorrhagic stroke. Bulletin of Experimental Biology and Medicine.2006;1:40-44. (In Russ.).
  14. Gannushkina IV. Pathomorphological mechanisms of cerebral circulation disorders and new directions in their prevention and treatment. Journal of Neuropathology and Psychiatry. 1996;(1):14-18. (In Russ.).
  15. Krishnan K, Campos PB, Nguyen TN, et al. Cerebral edema in intracerebral hemorrhage: pathogenesis, natural history, and potential treatments from translation to clinical trials. Front Stroke. 2023;2:1256664. https://doi.org/10.3389/fstro.2023.1256664
  16. Ratcliff JJ, Hall AJ, Porto E, et al. Early minimally invasive removal of intracerebral hemorrhage (ENRICH): study protocol for a multi-centered two-arm randomised adaptive trial. Front Neurol. 2023;14:1126958. https://doi.org/10.3389/fneur.2023.1126958
  17. Shao Z, Tu S, Shao A. Pathophysiological mechanisms and potential therapeutic targets in intracerebral hemorrhage. Front Pharmacol. 2019;10:1079. https://doi.org/10.3389/fphar.2019.01079
  18. Pfefferbaum A, Adalsteinsson E, Sullivan EV. In vivo structural imaging of the rat brain with a 3-T clinical human scanner. J Magn Reson Imaging. 2004;20(5):779-785. https://doi.org/10.1002/jmri.20181
  19. Allen JS, Damasio H, Grabowski TJ. Normal neuroanatomical variation in the human brain: an MRI-volumetric study. Am J Phys Anthropol. 2002;118(4):341-358. https://doi.org/10.1002/ajpa.10092
  20. Tao C, Keep RF, Xi G, Hua Y. CD47 blocking antibody accelerates hematoma clearance after intracerebral hemorrhage in aged rats. Transl Stroke Res. 2020;11(3):541-551. https://doi.org/10.1007/s12975-019-00745-4.
  21. Hanley DF, Thompson RE, Rosenblum M, et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 2019;393(10175):1021-1032. https://doi.org/10.1016/S0140-6736(19)30195-3
slide-cover
slide-cover
slide-cover
slide-cover

Recommended articles:

Enhancing medical rehabilitation outcomes for patients following ischemic stroke.S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(8-2):60-74

Aneurysmal subarachnoid hemorrhage.S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(8-2):28-36

Systemic inflammation in spastic forms of cerebral palsy: pathogenetic role and modulation possibilities using Mexidol in motor rehabilitation of pediatric patients.S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(5):74-82

Caffeine as a modulator of neurodegenerative processes: molecular targets, dose-dependent effects, and the influence of genetic polymorphism.Russian Journal of Preventive Medicine. 2026;29(5):85-90

The cerebroprotective effects of Mexidol in patients with hypertension.S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(4):113-118

Current evidence-based approaches to the treatment of vascular cognitive impairment.S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(4-2):78-85

Multimodal antioxidant therapy in ischemic stroke: from MIR trial to bedside.S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(12-2):64-71

Improving the quality of life and the possibility of pathogenetic therapy in adult patients with cerebral palsy.S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(10):75-84

The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol.S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(5):22-33

Modern aspects of chronic cerebral ischemia pathogenetic therapy.S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(12):106-113

Издательство «Медиа Сфера»
РекламаДоставка/ОплатаО насКонтактыОбучение для редакцийПолитика конфиденциальностиПолитика обработки персональных данныхПубличная оферта на реализацию издательской продукции
ЖурналыПодпискаАрхивКнигиПроекты
  • RuStore

© 1998-2026

  • Телефоны издательства:

  • +7 (495) 482-41-18
  • +7 (495) 482-43-29
  • Прямой телефон отдела подписки
    (только по вопросам заказов и доставки журналов)

  • +7 (800) 250-18-12
  • пн-пт с 10:00 до 18:00

  • Telegram
  • VK
info@mediasphera.ru
  • Почтовый адрес:

  • Издательство «Медиа Сфера»,
    а/я 54, Москва, Россия, 127238

  • RuStore

© 1998-2026